

BACTIVAM®

for diversion of the initial collection
Macopharma experience


**Guillaume de SAINT MARTIN
MACOPHARMA
F- 59338 TOURCOING**

- **Company profile**
- **Background**
- **Bactivam: *design***
- **Bactivam: *use***
- **New developments**

Macopharma

- ➔ **Turnover : > 150 million \$**
- ➔ **> 1000 employees**
- ➔ **International organization > 35 countries**
- ➔ **Largest supplier of in-line filters in Europe**
- ➔ **2nd largest supplier of Blood packs in Europe**

Standard Product



➡ **Increased awareness of bacterial contamination
in blood products**

➡ **Bruneau *et al***


VOX SANGUINIS 74, S1, 1998; p1039 (ISBT Oslo)

TRANSFUSION 2001; 41:74-81


***« excluding the first 15mL of blood may reduce the rate of
bacterial contamination in donations »***

- ➔ **First use: June 1998**
- ➔ **Guidelines French Blood Agency (09/19/2000)**
“The use of a sampling pouch should improve security in transfusion”
- ➔ **Experience in routine use (Macopharma)**
 > 4 million Bactivam[®] already used around Europe


Bactivam: design




1. Sampling pouch: Bactivam[®]
2. Sampling device: Vacuvam[®]
3. Clamp
4. Breakaway cannula
5. Needle protector : Secuvam[®]




1



2



3



4

→ Worldwide development

Australia, Germany, England, Spain...

→ Studies in progress

England (NBS) : validation

Spain: Platelet contamination

Product improvement

- **Clamp**
- **Breakaway cannula**